Top Page
Guangzhou Baiyunshan Pharmaceutical Holdings Company
(0874)
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model
Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 75.78B | 74.99B | 75.52B | 70.79B | 69.01B | 61.67B |
| Gross Profit | 12.38B | 12.52B | 14.19B | 13.28B | 13.23B | 10.44B |
| EBITDA | 4.18B | 4.90B | 6.49B | 5.00B | 5.82B | 4.68B |
| Net Income | 3.13B | 2.84B | 4.06B | 3.97B | 3.72B | 2.92B |
Balance Sheet | ||||||
| Total Assets | 82.42B | 81.68B | 78.59B | 74.67B | 66.12B | 59.76B |
| Cash, Cash Equivalents and Short-Term Investments | 11.83B | 22.72B | 21.31B | 22.56B | 22.38B | 19.47B |
| Total Debt | 13.27B | 12.37B | 11.70B | 11.43B | 9.92B | 9.56B |
| Total Liabilities | 42.61B | 43.91B | 41.91B | 41.03B | 34.79B | 31.55B |
| Stockholders Equity | 37.76B | 35.90B | 34.92B | 32.07B | 29.06B | 26.14B |
Cash Flow | ||||||
| Free Cash Flow | -16.72M | 2.31B | 2.48B | 5.62B | 4.42B | ― |
| Operating Cash Flow | -3.40B | 3.44B | 4.10B | 7.00B | 5.67B | 585.19M |
| Investing Cash Flow | -4.72B | -5.96B | -3.11B | ― | ― | ― |
| Financing Cash Flow | 1.92B | -1.01B | -1.98B | 45.95M | ― | 1.44B |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $44.96B | 9.63 | 7.86% | 6.80% | 1.13% | -13.53% | |
74 Outperform | $33.45B | 12.13 | 14.91% | 3.74% | -0.45% | 9.00% | |
73 Outperform | HK$31.09B | 14.75 | 12.65% | 3.09% | 10.56% | -13.58% | |
68 Neutral | HK$31.10B | 10.23 | 5.90% | 2.76% | ― | ― | |
65 Neutral | $24.88B | 6.94 | 21.02% | 4.88% | 0.39% | 4.94% | |
65 Neutral | $77.88B | 17.22 | 6.75% | 1.56% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a joint stock company based in China, operating in the pharmaceutical industry, known for its extensive range of pharmaceutical products and healthcare services.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited reported a significant increase in its financial performance for the third quarter of 2025. The company’s income from operations rose by 9.74% compared to the same period in 2024, and the net profit attributable to shareholders increased by 30.28%. Despite these positive results, the company experienced a substantial decrease in net cash flow from operating activities, which dropped by 162.45%. This financial report highlights the company’s strong profitability growth, although it faces challenges in cash flow management.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has revised the rules for its Nomination and Remuneration Committee to improve management structure and standardize procedures for appointing directors and senior management. These changes aim to ensure that the board members have the appropriate skills and diversity to support the company’s strategic goals. The committee will focus on formulating criteria for selecting and evaluating directors and senior management, as well as developing remuneration policies and plans. This move is expected to strengthen the company’s governance and align its leadership with its strategic objectives.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has approved a Board Diversity Policy to enhance corporate governance and support sustainable development. This policy emphasizes the importance of diversity in the boardroom, considering factors such as gender, age, cultural background, and professional experience in the selection of board members. The Nomination and Remuneration Committee is tasked with ensuring the implementation of this policy, with the aim of achieving a balanced and effective board composition. The company will report annually on the board’s diversity and the policy’s implementation, reflecting its commitment to inclusivity and strategic growth.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced a supplementary disclosure regarding its acquisition of an 11.04% equity interest in a target company. The transaction involves a significant financial stake, with the book value of the equity attributable to the target shares being over 867 million RMB as of June 2025. The seller, AHAPL, is now indirectly owned by Blazing Star Investors, LLC, following a privatization and restructuring of its former parent company, Walgreens Boots Alliance. This acquisition is expected to impact the company’s market positioning and potential growth opportunities.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced a board meeting scheduled for October 28, 2025, to review and approve the unaudited financial results for the nine months ending September 30, 2025. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential strategic decisions moving forward.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has appointed Mr. Chen Jiehui as the vice chairperson of its board, effective from September 26, 2025. Mr. Chen, who has extensive experience in strategic management and corporate governance, will serve until the conclusion of the board’s ninth session. This appointment is expected to strengthen the company’s leadership and strategic direction, potentially impacting its industry positioning and stakeholder relationships.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced the composition of its board of directors, which includes both executive and independent non-executive directors. The board has established four committees, each with specific roles and responsibilities, to enhance the company’s governance and strategic decision-making processes.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced that its controlled partnership enterprise, GP Fund II, has entered into a Share Transfer Agreement to acquire an 11.04% equity interest in a target company from AHAPL, an independent third party. The acquisition, valued at RMB 748,807,492.58, aims to enhance strategic cooperation between the involved entities and is classified as a disclosable transaction under Hong Kong Listing Rules, exempt from shareholder approval.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced the resolutions passed at its ninth board of directors’ twenty-ninth meeting. Key decisions include the approval of Guangzhou Guangyao’s acquisition of an 11.04% stake in Nanjing Pharmaceutical Company and the election of Chen Jiehui as the vice chairman of the board. These moves are expected to strengthen the company’s strategic position and enhance its governance structure.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company successfully held its second extraordinary general meeting (EGM) on 26 September 2025, where all proposed resolutions were approved by shareholders. The meeting, which adhered to the relevant legal and company provisions, saw participation from a significant portion of shareholders, indicating strong support for the company’s strategic decisions.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced the convening of its second extraordinary general meeting (EGM) in 2025, scheduled for September 26. Key resolutions to be considered include amendments to the company’s Articles of Association, the dissolution of the Supervisory Committee, changes to the Rules of Procedures for Shareholders’ Meetings and the Board of Directors, and the election of a new executive director. These resolutions, if passed, could impact the company’s governance structure and operational procedures.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced a disclosable transaction involving the disposal of accounts receivable by its subsidiary, GP Corp., to Industrial Securities Asset Management. This transaction, valued at approximately RMB501.96 million, is part of a series of similar transactions conducted within a 12-month period. The aggregate of these transactions exceeds a 5% but remains below a 25% threshold, thus requiring reporting and announcement under the Hong Kong Listing Rules, though it is exempt from shareholder approval. This move reflects the company’s strategic financial management and asset optimization efforts.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, a prominent player in the biopharmaceutical and healthcare sector, is known for its extensive operations in traditional Chinese medicine and healthcare products. The company’s latest earnings report for the first half of 2025 highlights a mixed financial performance, with a slight increase in operating revenue but a decrease in total profit and net profit attributable to shareholders. Key financial metrics reveal a 1.93% increase in operating revenue to RMB41.83 billion, while total profit and net profit attributable to shareholders decreased by 4.30% and 1.31%, respectively. The company attributes these declines to challenges in certain business segments due to insufficient demand and intensified competition. Strategic initiatives during the period included strengthening the pharmaceutical manufacturing industry chain, expanding international market presence, and enhancing digital transformation efforts. Looking ahead, Guangzhou Baiyunshan plans to focus on core industry chain development, international expansion, and scientific research innovation to drive future growth.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced proposed amendments to its Articles of Association, Rules of Procedures for Shareholders’ Meetings, and Rules of Procedures for the Board of Directors, alongside the dissolution of its Supervisory Committee. These changes are in response to the new Company Law and aim to enhance corporate governance and operational standardization. The statutory functions of the Supervisory Committee will now be handled by the Audit Committee, subject to shareholder approval at the upcoming general meeting.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$21.70 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced the proposed appointment of Mr. Chen Jiehui as an executive director, pending shareholder approval. Mr. Chen brings extensive experience in strategic management and corporate governance, and his appointment is expected to strengthen the company’s leadership and operational capabilities.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$21.70 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced an interim cash dividend of RMB 0.4 per share for the first half of 2025, with a payment date set for 26 September 2025. The announcement outlines the withholding tax obligations for different categories of shareholders, impacting non-resident enterprises and individual investors, which may influence investor decisions and the company’s financial strategy.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$21.70 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced its 2025 interim report for the period ending June 30, 2025. The company plans to distribute an interim cash dividend of RMB0.40 per share, totaling RMB650,316,379.60. This decision reflects the company’s commitment to returning value to its shareholders. The financial reports were prepared according to China Accounting Standards and were unaudited.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$21.70 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced the distribution of its 2025 interim dividend, set at RMB0.40 per share, payable in cash. The dividend will be distributed to shareholders whose names appear on the register by September 8, 2025, with payments expected on September 26, 2025. The announcement outlines the tax implications for different categories of shareholders, including non-resident enterprise shareholders who will face a 10% withholding tax, while resident enterprise shareholders are exempt. This move reflects the company’s commitment to returning value to its shareholders and may impact its financial standing and investor relations.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$21.70 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced that its board of directors will meet on August 15, 2025, to consider and approve the unaudited financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:0874) stock is a Sell with a HK$16.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.